Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.71

+0.4%

Dec 24 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1873)	10/23/2000 11:40:38 PM
From: seminole	Read Replies (2) of 52153

Peter <<<SUPG, why it has tanked so badly?>>> The fall from $28 to $12 occurred after a Prudential downgraded SUPG from a Strong Buy all the way to a Hold on Aug 31. Delays in the Phase III trial was given as the reason. However, the retirement of their Medical Director and resignation of their Chief Scientific Officer reported on Aug 17 has many thinking there is more than just a short delay here. MOGN's Phase III, some points to consider as presented during the CC: They consulted with the FDA before selecting 1x per week. They have had no patient drop outs in 1x per week. Pancreatic trial has survival time as its end point not tumor shrinkage. They still have not reached MTD in 1x per week. The MTD for 1x per week will be above the MTD of 5x per week. The FDA is allowing 1x per week to be used in the Phase III. good luck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next